• SB525334: TGF-beta1 Receptor Inhibitor for Fibrosis & Wound

  2026-07-02

  SB525334, a potent and selective TGF-beta1 receptor inhibitor, empowers researchers to dissect fibrotic and wound-healing pathways with precision. This guide demystifies its application in advanced fibrosis and chronic wound models, providing actionable workflows, troubleshooting insights, and translational context from cutting-edge studies.

• Triamcinolone: Technical Guidance for In Vitro Glucocorticoi

  2026-07-02

  Triamcinolone (SKU B1859) is a synthetic glucocorticoid agonist designed for precise modulation of glucocorticoid receptor signaling in cellular models. It addresses the need for high-purity compounds in anti-inflammatory and immunosuppression research but is not suitable for diagnostic or clinical applications.

• Thiazovivin Protocols: ROCK Inhibitor for Stem Cell Research

  2026-07-01

  Thiazovivin is a potent ROCK inhibitor used to enhance induced pluripotent stem cell generation and support the survival of human embryonic stem cells during dissociation and reprogramming workflows. It is not intended for diagnostic or therapeutic use and should not be used where long-term solution stability is required.

• Cyclophilin A Is Essential for Cyclosporin Immunosuppression

  2026-07-01

  This study demonstrates that cyclophilin A is indispensable for cyclosporin-mediated immunosuppression in mice. The findings refine our mechanistic understanding of how cyclosporin inhibits T-cell activation and inform the design of immunosuppression assays and disease models.

• Baicalein: Applied Protocols for Cancer and Inflammation Ass

  2026-06-30

  Baicalein (5,6,7-trihydroxy-2-phenylchromen-4-one) empowers researchers to dissect the 12-LOX pathway, enabling precise apoptosis and inflammation studies. This guide translates cutting-edge findings and troubleshooting insights into actionable workflows for reproducible cancer and metabolic enzyme research.

• Epigenetic Mechanisms of Prenatal Dexamethasone-Induced Bone

  2026-06-30

  This study reveals that prenatal dexamethasone exposure (PDE) impairs bone development in mice by reducing osteoprogenitor proliferation via epigenetic modifications at the Mkp-1 gene locus. By elucidating how altered histone methylation promotes MKP-1 expression and disrupts MAPK signaling, the research highlights new targets for mitigating glucocorticoid-induced skeletal deficits.

• Dual AMPA/NMDA Blockade Mitigates Soman-Induced Neurotoxicit

  2026-06-29

  The reference study demonstrates that IEM-1925, a dual AMPA/NMDA glutamate receptor antagonist, markedly reduces seizures, neurodegeneration, and cognitive deficits in a rat model of soman-induced status epilepticus. These findings highlight the translational potential of targeting glutamate-mediated excitotoxicity for neuroprotection against organophosphorus nerve agent exposure.

• Capillarisenol C Induces ER Stress-Mediated Autophagic Death

  2026-06-29

  This study identifies Capillarisenol C, a novel bisphenol from Artemisia capillaris, as a potent inducer of ER stress-mediated cytotoxic autophagy in hepatocellular carcinoma cells. The findings clarify the mechanistic role of the PERK-eIF2α and IRE1 axes in Cap C-induced cell death and highlight the utility of 4-Phenylbutyric acid (4-PBA) as a chemical chaperone to dissect ER stress pathways in cancer research.

• LY2109761: Deep-Dive into TGF-β Signaling Modulation in Canc

  2026-06-28

  Explore the advanced mechanisms and unique experimental insights of LY2109761, a TGF-β receptor type I and II dual inhibitor. This article delivers a deeper analysis of pathway modulation and its translational significance beyond standard reviews.

• Improving In Vitro Drug Response Evaluation in Cancer Resear

  2026-06-27

  Schwartz's dissertation introduces a systematic approach for dissecting anti-cancer drug responses in vitro, distinguishing growth inhibition from cell death to provide deeper mechanistic understanding. These advances help refine preclinical testing protocols and support more accurate assessment of novel PARP inhibitors like AZD2461 in breast cancer and BRCA1-mutated tumor models.

• LDN-193189: ALK Inhibitor Protocols for BMP Pathway Assays

  2026-06-26

  LDN-193189, a nanomolar-potency ALK inhibitor from APExBIO, empowers researchers to dissect BMP signaling with precision—enabling reliable modulation of Smad1/5/8 phosphorylation and epithelial barrier protection. Streamline cell and animal workflows using reproducible, evidence-backed protocols and troubleshooting insights for robust experimental outcomes.

• Prednisolone: Deep Dive into Synthetic Glucocorticoids in Ta

  2026-06-26

  Explore the science behind Prednisolone as a synthetic glucocortoid, its unique advantages in inflammation modulation, and its evolving role in targeted protein degradation research. This cornerstone article provides a comprehensive, mechanism-focused perspective for advanced assay development.

• Baicalin for KEAP1-NRF2/HO-1 Pathway Modulation in Research

  2026-06-25

  Baicalin, a high-purity flavone glycoside, unlocks precise KEAP1-NRF2/HO-1 pathway modulation for both neuroplasticity and cancer research. Its unique ability to restore ocular dominance plasticity and enhance therapy response sets it apart for advanced experimental designs.

• SIS3 Smad3 Inhibitor: Precision in Fibrosis & OA Research

  2026-06-25

  SIS3 stands out as a potent, selective Smad3 inhibitor, enabling researchers to dissect TGF-β pathway dynamics in fibrotic and osteoarthritic models with unmatched specificity. This guide translates recent breakthroughs—like the regulation of ADAMTS-5 in OA—into actionable protocols and troubleshooting insights for robust, reproducible results.

• Fluconazole in Translational Antifungal Research: Mechanisms

  2026-06-24

  This thought-leadership article explores the mechanistic underpinnings of Fluconazole as a fungal cytochrome P450 enzyme 14α-demethylase inhibitor and its strategic application in translational research. It provides insights into biofilm resistance, protocol guidance, and outlook for antifungal innovation, with structured evidence integration and actionable recommendations for researchers.

16205 records 1/1081 page Next 12345 下5页 Last page